ArticleInternational journal of endocrinology2016
Myo-Inositol in the Treatment of Teenagers Affected by PCOS.
Article in International journal of endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis.Endocrine · 2018Pooled it
- Article
- Probiotics and Polycystic Ovary Syndrome: A Perspective for Management in Adolescents with Obesity.Nutrients · 2023Review
- Treatment with Myo-Inositol Does Not Improve the Clinical Features in All PCOS Phenotypes.Biomedicines · 2023Article
- PCOS in Adolescents-Ongoing Riddles in Diagnosis and Treatment.Journal of clinical medicine · 2023Review
- Polycystic Ovary Syndrome in Adolescence: Challenges in Diagnosis and Management.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022Article
- Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS.International journal of molecular sciences · 2020Review
- Inositols in PCOS.Molecules (Basel, Switzerland) · 2020Review
- Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS.International journal of molecular sciences · 2020Review
- Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary.International journal of endocrinology · 2020Review
- Emerging Topics in Cardiometabolic and Psychologic Sequelae, Pathogenesis, and Treatment of Polycystic Ovarian Syndrome: A Review.Children (Basel, Switzerland) · 2019Review
- Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials.Endocrine connections · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective. To compare the effectiveness of myo-inositol (MI) and oral contraceptive pills (OCPs) in monotherapy and MI in combination with OCPs in the treatment of teenagers affected by polycystic ovary syndrome (PCOS). Methods. 61 adolescent girls aged 13-19 years, with PCOS, were involved in the prospective, open-label study. Patients were randomized into three groups: I group, 20 patients receiving drospirenone 3 mg/ethinyl estradiol 30 μg; II group, 20 patients receiving 4 g myo-inositol plus 400 mg folic acid; III group, 21 patients receiving both medications. Results. After receiving MI significant reduction in weight, BMI, glucose, C-peptide, insulin, HOMA-IR, FT, and LH was detected. The levels of SHBG, TT, FAI, DHEA-S, and AMH did not change statistically significantly. After receiving OCPs weight and BMI slightly increased, but metabolic parameters did not change. Combination of MI and OCPs did not change weight and BMI, but reduction in C-peptide, insulin, and HOMA-IR was detected. TT, FT, FAI, DHEA-S, LH, and AMH levels decreased and SHBG increased. Conclusions. Administration of MI is a safe and effective method to prevent and correct metabolic disorders in teenagers affected by PCOS. With combination of MI and OCPs antiandrogenic effects are enhanced, negative impact of OCPs on weight gain is balanced, and metabolic profile is improved.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.